<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170300</url>
  </required_header>
  <id_info>
    <org_study_id>Care-HF 2.02.02</org_study_id>
    <nct_id>NCT00170300</nct_id>
  </id_info>
  <brief_title>Care-HF CArdiac Resynchronization in Heart Failure</brief_title>
  <official_title>Outcome Trial (Long Term)to Evaluate the Effects of Cardiac Resynchronization Therapy on the Mortality and Morbidity of Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <brief_summary>
    <textblock>
      The CARE-HF trial evaluates the effects of Cardiac Resynchronization (CR) therapy on the
      mortality and morbidity of patients with heart failure due to left ventricular systolic
      dysfunction already receiving diuretics and optimal medical therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      813 patients enrolled 82 centers in 12 countries (Austria, Belgium, Denmark, Finland, France,
      Germany, Italy, Netherlands, Spain, Sweden, Switzerland, and UK)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>May 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality or unplanned cardiovascular hospitalization.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality or unplanned hospitalization for or with worsening Heart Failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and not in hospital for unplanned cardiovascular cause</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and not in hospital for any reason</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class at 90 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL at 90 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of study status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MECHANISTIC OUTCOME:Echocardiographic parameters, Neurohormonal parameters, Therapy delivery assessment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HEALTH ECONOMIC OUTCOME:Cost effectiveness of cardiac resynchronization will be assessed.</measure>
  </secondary_outcome>
  <enrollment>813</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Cardiac Resynchronisation (pacing) device</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure for at least 6 weeks requiring loop diuretics

          -  Currently in NYHA class III/IV

          -  A high standard of pharmacological therapy

          -  LV systolic dysfunction and dilation (EF &lt;=35%; EDD &gt;30mm/height in metres)

          -  QRS &gt;=120 ms Dyssynchrony confirmed by echo if QRS 120-149 ms (Aortic pre-ejection
             delay &gt;140ms, Interventricular mechanical delay &gt;40 ms, Delayed activation of
             postero-lateral LV wall)

        Exclusion Criteria:

          -  Age &lt; 18 years old or age &lt; legal age defined in the country in case different

          -  Chronic atrial fibrillation within 6 weeks prior to randomization;

          -  Impairment of left ventricular function not related to left ventricular systolic
             function

          -  Potentially reversible forms of cardiomyopathy:

          -  Cardiac surgery, percutaneous coronary intervention, cardiomyoplasty, myocardial
             infarction,unstable severe angina or stroke within 6 weeks before randomization

          -  A conventional indication for bradyarrhythmia pacing exists;

          -  A conventional indication for an ICD exists

          -  A pacemaker or ICD has already been implanted;

          -  In-Patients requiring continuous intravenous therapy for Heart Failure;

          -  Life expectancy &lt; 1 year for disease unrelated to Heart Failure;

          -  Pregnancy or childbearing potential and not on reliable contraceptive;

          -  Mechanical tricuspid valve;

          -  Anticipated compliance problem or participation in another trial;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Cleland, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Hull; Department of Cardiology; United Kingdom</affiliation>
  </overall_official>
  <link>
    <url>http://www.medtronic.com/physician/hf/care-hf.html</url>
    <description>The page contains relavant information of the trial including published results</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <keyword>Cardiac resynchronisation therapy (CRT therapy),</keyword>
  <keyword>all-cause mortality,</keyword>
  <keyword>quality of life assesment,</keyword>
  <keyword>echocardiographic left ventricular function,</keyword>
  <keyword>CRT and neurohormonal activation,</keyword>
  <keyword>CRT and health economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

